DDInter740 DDInter1731
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is downregulated by {v} (Compound) Sunitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Cardiac failure congestive
Cardiac failure congestive {u} (Side Effect) is caused by {v} (Compound) Sunitinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) regulates {v} (Gene) STK10
STK10 {u} (Gene) is bound by {v} (Compound) Sunitinib
Flecainide {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) is regulated by {v} (Gene) YES1
YES1 {u} (Gene) is bound by {v} (Compound) Sunitinib
Flecainide {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Sunitinib
Flecainide {u} (Compound) downregulates {v} (Gene) RRM2
RRM2 {u} (Gene) is regulated by {v} (Gene) PRPF4B
PRPF4B {u} (Gene) is bound by {v} (Compound) Sunitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Cardiac failure congestive
Cardiac failure congestive {u} (Side Effect) is caused by {v} (Compound) Metoclopramide
Metoclopramide {u} (Compound) resembles {v} (Compound) Sunitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Renal failure
Renal failure {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sunitinib
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound)
Flecainide (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is downregulated by Sunitinib (Compound)
Flecainide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Sunitinib (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) regulates STK10 (Gene) and STK10 (Gene) is bound by Sunitinib (Compound)
Flecainide (Compound) upregulates AARS (Gene) and AARS (Gene) is regulated by YES1 (Gene) and YES1 (Gene) is bound by Sunitinib (Compound)
Flecainide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by kidney cancer (Disease) and kidney cancer (Disease) is treated by Sunitinib (Compound)
Flecainide (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is regulated by PRPF4B (Gene) and PRPF4B (Gene) is bound by Sunitinib (Compound)
Flecainide (Compound) causes Cardiac failure congestive (Side Effect) and Cardiac failure congestive (Side Effect) is caused by Metoclopramide (Compound) and Metoclopramide (Compound) resembles Sunitinib (Compound)
Flecainide (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib